The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome

Kinanga Kiaco; António Sebastião Rodrigues; Virgílio do Rosário; José Pedro Gil; Dinora Lopes

doi:10.1186/s12936-017-2006-6

The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome

Kinanga Kiaco, António Sebastião Rodrigues, Virgílio do Rosário, José Pedro Gil, Dinora Lopes

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

89 Downloads (Pure)

Abstract

Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.

Original language	English
Pages (from-to)	383-389
Number of pages	6
Journal	Malaria Journal
Volume	Vol. 16
Issue number	n.º 1
DOIs	https://doi.org/10.1186/s12936-017-2006-6
Publication status	Published - 21 Sept 2017

Keywords

Angola
Artemether-lumefantrine
CYP450
Human polymorphism
MDR1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s12936-017-2006-6Licence: CC BY

The drug transporter ABCB1 3435CT SNP influences artemether-lumefantrine treatment outcomeFinal published version, 802 KBLicence: CC BY

Cite this

@article{0b90a419ea77489491906e1b2641b203,

title = "The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome",

abstract = "Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.",

keywords = "Angola, Artemether-lumefantrine, CYP450, Human polymorphism, MDR1",

author = "Kinanga Kiaco and Rodrigues, {Ant{\'o}nio Sebasti{\~a}o} and {do Ros{\'a}rio}, Virg{\'i}lio and Gil, {Jos{\'e} Pedro} and Dinora Lopes",

year = "2017",

month = sep,

day = "21",

doi = "10.1186/s12936-017-2006-6",

language = "English",

volume = "Vol. 16",

pages = "383--389",

journal = "Malaria Journal",

publisher = "BioMed Central (BMC)",

number = "n.º 1",

}

TY - JOUR

T1 - The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome

AU - Kiaco, Kinanga

AU - Rodrigues, António Sebastião

AU - do Rosário, Virgílio

AU - Gil, José Pedro

AU - Lopes, Dinora

PY - 2017/9/21

Y1 - 2017/9/21

N2 - Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.

AB - Malaria treatment performance is potentially influenced by pharmacogenetic factors. This study reports an association study between the ABCB1 c.3435C>T, CYP3A4*1B (g.-392A>G), CYP3A5*3 (g.6986A>G) SNPs and artemether + lumefantrine treatment outcome in 103 uncomplicated malaria patients from Angola. No significant associations with the CYP3A4*1B and CYP3A5*3 were observed, while a significant predominance of the ABCB1 c.3435CC genotype was found among the recurrent infection-free patients (p < 0.01), suggesting a role for this transporter in AL inter-individual performance.

KW - Angola

KW - Artemether-lumefantrine

KW - CYP450

KW - Human polymorphism

KW - MDR1

UR - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609073/

U2 - 10.1186/s12936-017-2006-6

DO - 10.1186/s12936-017-2006-6

M3 - Article

C2 - 28934955

VL - Vol. 16

SP - 383

EP - 389

JO - Malaria Journal

JF - Malaria Journal

IS - n.º 1

ER -

The drug transporter ABCB1 c.3435C>T SNP influences artemether-lumefantrine treatment outcome

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this